The Versamune® nano-platform is based on synthetic positively-charged lipids, and is protected by several patents.

Versamune® works when administered together with a disease or cancer-specific antigen to prime and target a T-cell response specifically against cells displaying that particular antigen. Treatment with Versamune®-based immunotherapies results in stimulation of both the innate and adaptive arms of the immune system. Preclinical studies also suggest significant reduction in tumor defense mechanisms, leading to powerful anti-tumor efficacy.

The Versamune® platform is built on all three critical components of cancer immunotherapy that have been demonstrated to be clinically important.

PDS Biotechnology illustration
  • About Us

    PDS Biotechnology Corporation logo image

    PDS Biotechnology is a clinical stage biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.

  • Contact Us

    PDS Biotechnology Corporation
    Commercialization Center for Innovative Technologies (CCIT)

    675 US Highway One
    North Brunswick, NJ 08902

    Tel: 732-640-0145
    Fax: 732-640-0144